1. Araújo C, Silva JP, Antunes P, Fernandes JM, Dias C, Pereira H, et al. A comparative study between two central veins for the introduction of totally implantable venous access devices in 1201 cancer patients. Eur J Surg Oncol. 2008;34:222–6.
2. Rouzrokh M, Shamsian BS, KhaleghNejad Tabari A, Mahmoodi M, Kouranlo J, Manafzadeh G, et al. Totally implantable subpectoral vs. subcutaneous port systems in children with malignant diseases. Arch Iran Med. 2009;12:389–94.
3. Biffi R, de Braud F, Orsi F, Pozzi S, Mauri S, Goldhirsch A, et al. Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Ann Oncol. 1998;9:767–73.
4. Ahmadi J, Izadyar M, Ashjaei B, Klantari M, Nahvi H, Joodi M, et al. Study of advantages and disadvantages of totally implantable venous access devices. Acta Med Iran. 2006;44:199–202.
5. CDC: 2011 Guidelines for the Prevention of Intravascular Catheter-Related Infections. http://www.cdc.gov/hicpac/BSI/BSI-guidelines-2011.html